{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:47:04Z","timestamp":1765234024641,"version":"3.41.2"},"posted":{"date-parts":[[2025,7,17]]},"group-title":"In Review","reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,7,2]]},"abstract":"<title>Abstract<\/title>\n        <p>AAV-based gene therapy targeting adipose tissue has been underdeveloped due to lack of adipose-tropic AAV vectors with sufficient transduction efficiency. We previously demonstrated that an engineered capsid variant of Rec2 capsid with F503Y, Y708D and K709I substitution (named V7 capsid) exhibited highly selective adipo-tropism while ablating liver transduction upon intraperitoneal injection or intravenous injection. In this study, we investigated the feasibility of subcutaneous administration of V7 vector harboring human leptin (V7-LEP) in a congenital leptin deficiency model <italic>ob\/ob<\/italic> mice. Subcutaneous administration of V7-LEP vector at a low dose of 4x10<sup>10<\/sup> viral genome per mouse restored circulating leptin levels and completely normalized metabolic abnormalities associated with leptin deficiency. In an ongoing long-term experiment, one-time subcutaneous administration of V7-LEP to extreme obese <italic>ob\/ob<\/italic> mice has led to sustained weight loss at least up to 9 months post injection associated with stable circulating human leptin levels throughout the long-term study. These data indicate subcutaneous injection is a feasible and relevant administration route for gene therapy targeting adipose tissue, and V7-LEP is highly efficacious for congenital leptin deficiency and potentially other lipodystrophy disorders with leptin deficiency.<\/p>","DOI":"10.21203\/rs.3.rs-7030870\/v1","type":"posted-content","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T08:24:36Z","timestamp":1752740676000},"source":"Crossref","is-referenced-by-count":1,"title":["Subcutaneous administration of adipose-tropic gene therapy for congenital leptin deficiency"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0322-4985","authenticated-orcid":false,"given":"Lei","family":"Cao","sequence":"first","affiliation":[{"name":"Ohio State University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[{"name":"The Ohio State University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xunchang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.omtm.2019.01.008","article-title":"Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors","volume":"12","author":"Buning H","year":"2019","unstructured":"Buning H, Srivastava A. Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors. Mol Ther Methods Clin Dev. 2019;12:248\u201365.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2022.09.015","article-title":"AAV vectors: The Rubik's cube of human gene therapy","author":"Pupo A","year":"2022","unstructured":"Pupo A, Fernandez A, Low SH, Francois A, Suarez-Amaran L, Samulski RJ. AAV vectors: The Rubik's cube of human gene therapy. Mol Ther. 2022.","journal-title":"Mol Ther"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/d41573-021-00017-7","article-title":"The clinical landscape for AAV gene therapies","volume":"20","author":"Kuzmin DA","year":"2021","unstructured":"Kuzmin DA, Shutova MV, Johnston NR, Smith OP, Fedorin VV, Kukushkin YS, et al. The clinical landscape for AAV gene therapies. Nat Rev Drug Discov. 2021;20(3):173\u20134.","journal-title":"Nat Rev Drug Discov"},{"key":"ref4","first-page":"809118","article-title":"Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings","volume":"8","author":"Au HKE","year":"2021","unstructured":"Au HKE, Isalan M, Mielcarek M. Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings. Front Med (Lausanne). 2021;8:809118.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrg2988","article-title":"Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges","volume":"12","author":"Mingozzi F","year":"2011","unstructured":"Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. 2011;12(5):341\u201355.","journal-title":"Nat Rev Genet"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.omtm.2020.09.009","article-title":"Adipose Tissue: An Emerging Target for Adeno-associated Viral Vectors","volume":"19","author":"Bates R","year":"2020","unstructured":"Bates R, Huang W, Cao L. Adipose Tissue: An Emerging Target for Adeno-associated Viral Vectors. Mol Ther Methods Clin Dev. 2020;19:236\u201349.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"e60361","DOI":"10.1371\/journal.pone.0060361","article-title":"Assessment of tropism and effectiveness of new primate-derived hybrid recombinant AAV serotypes in the mouse and primate retina","volume":"8","author":"Charbel Issa P","year":"2013","unstructured":"Charbel Issa P, De Silva SR, Lipinski DM, Singh MS, Mouravlev A, You Q, et al. Assessment of tropism and effectiveness of new primate-derived hybrid recombinant AAV serotypes in the mouse and primate retina. PLoS ONE. 2013;8(4):e60361.","journal-title":"PLoS ONE"},{"key":"ref8","article-title":"Adipose tissue insulin receptor knockdown via a new primate-derived hybrid recombinant AAV serotype","volume":"1","author":"Liu X","year":"2014","unstructured":"Liu X, Magee D, Wang C, McMurphy T, Slater A, During M et al. Adipose tissue insulin receptor knockdown via a new primate-derived hybrid recombinant AAV serotype. Mol Ther Methods Clin Dev. 2014;1.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2337\/db16-0876","article-title":"Hepatic Expression of Adenovirus 36 E4ORF1 Improves Glycemic Control and Promotes Glucose Metabolism Through AKT Activation","volume":"66","author":"McMurphy TB","year":"2017","unstructured":"McMurphy TB, Huang W, Xiao R, Liu X, Dhurandhar NV, Cao L. Hepatic Expression of Adenovirus 36 E4ORF1 Improves Glycemic Control and Promotes Glucose Metabolism Through AKT Activation. Diabetes. 2017;66(2):358\u201371.","journal-title":"Diabetes"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.omtm.2017.06.002","article-title":"Targeting Visceral Fat by Intraperitoneal Delivery of Novel AAV Serotype Vector Restricting Off-Target Transduction in Liver","volume":"6","author":"Huang W","year":"2017","unstructured":"Huang W, Liu X, Queen NJ, Cao L. Targeting Visceral Fat by Intraperitoneal Delivery of Novel AAV Serotype Vector Restricting Off-Target Transduction in Liver. Mol Ther Methods Clin Dev. 2017;6:68\u201378.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.molmet.2019.09.008","article-title":"Adipose PTEN regulates adult adipose tissue homeostasis and redistribution via a PTEN-leptin-sympathetic loop","volume":"30","author":"Huang W","year":"2019","unstructured":"Huang W, Queen NJ, McMurphy TB, Ali S, Cao L. Adipose PTEN regulates adult adipose tissue homeostasis and redistribution via a PTEN-leptin-sympathetic loop. Mol metabolism. 2019;30:48\u201360.","journal-title":"Mol metabolism"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpnec.2020.100013","article-title":"Adipose PTEN acts as a downstream mediator of a brain-fat axis in environmental enrichment","volume":"4","author":"Huang W","year":"2020","unstructured":"Huang W, Queen NJ, McMurphy TB, Ali S, Wilkins RK, Appana B et al. Adipose PTEN acts as a downstream mediator of a brain-fat axis in environmental enrichment. Compr Psychoneuroendocrinol. 2020;4.","journal-title":"Compr Psychoneuroendocrinol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.omtm.2020.12.011","article-title":"Visceral adipose tissue-directed FGF21 gene therapy improves metabolic and immune health in BTBR mice","volume":"20","author":"Queen NJ","year":"2021","unstructured":"Queen NJ, Bates R, Huang W, Xiao R, Appana B, Cao L. Visceral adipose tissue-directed FGF21 gene therapy improves metabolic and immune health in BTBR mice. Mol Ther Methods Clin Dev. 2021;20:409\u201322.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"9","key":"ref14","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.4049\/jimmunol.2100313","article-title":"Adipocyte CD1d Gene Transfer Induces T Cell Expansion and Adipocyte Inflammation in CD1d Knockout Mice","volume":"208","author":"Xiao R","year":"2022","unstructured":"Xiao R, Mansour AG, Huang W, Hassan QN 2nd, Wilkins RK, Komatineni SV, et al. Adipocyte CD1d Gene Transfer Induces T Cell Expansion and Adipocyte Inflammation in CD1d Knockout Mice. J Immunol. 2022;208(9):2109\u201321.","journal-title":"J Immunol"},{"issue":"9","key":"ref15","doi-asserted-by":"crossref","first-page":"eabj9109","DOI":"10.1126\/sciadv.abj9109","article-title":"eNAMPT actions through nucleus accumbens NAD(+)\/SIRT1 link increased adiposity with sociability deficits programmed by peripuberty stress","volume":"8","author":"Morato L","year":"2022","unstructured":"Morato L, Astori S, Zalachoras I, Rodrigues J, Ghosal S, Huang W, et al. eNAMPT actions through nucleus accumbens NAD(+)\/SIRT1 link increased adiposity with sociability deficits programmed by peripuberty stress. Sci Adv. 2022;8(9):eabj9109.","journal-title":"Sci Adv"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.omtm.2022.07.018","article-title":"Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper","volume":"26","author":"Yang TY","year":"2022","unstructured":"Yang TY, Braun M, Lembke W, McBlane F, Kamerud J, DeWall S, et al. Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper. Mol Ther Methods Clin Dev. 2022;26:471\u201394.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer","volume":"28","author":"Verdera HC","year":"2020","unstructured":"Verdera HC, Kuranda K, Mingozzi F. AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer. Mol Ther. 2020;28(3):723\u201346.","journal-title":"Mol Ther"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"110930","DOI":"10.1016\/j.isci.2024.110930","article-title":"Development of an adipose-tropic AAV capsid ablating liver tropism","volume":"27","author":"Huang W","year":"2024","unstructured":"Huang W, Bates R, Appana B, Mohammed T, Cao L. Development of an adipose-tropic AAV capsid ablating liver tropism. iScience. 2024;27(10):110930.","journal-title":"iScience"},{"issue":"7","key":"ref19","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.celrep.2016.01.041","article-title":"Leptin Raises Defended Body Temperature without Activating Thermogenesis","volume":"14","author":"Fischer AW","year":"2016","unstructured":"Fischer AW, Hoefig CS, Abreu-Vieira G, de Jong JMA, Petrovic N, Mittag J, et al. Leptin Raises Defended Body Temperature without Activating Thermogenesis. Cell Rep. 2016;14(7):1621\u201331.","journal-title":"Cell Rep"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4158\/EP09154.RA","article-title":"Clinical classification and treatment of congenital and acquired lipodystrophy","volume":"16","author":"Chan JL","year":"2010","unstructured":"Chan JL, Oral EA. Clinical classification and treatment of congenital and acquired lipodystrophy. Endocr Pract. 2010;16(2):310\u201323.","journal-title":"Endocr Pract"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2011-1159","article-title":"Clinical review#: Lipodystrophies: genetic and acquired body fat disorders","volume":"96","author":"Garg A","year":"2011","unstructured":"Garg A. Clinical review#: Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96(11):3313\u201325.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.2337\/db16-0327","article-title":"FGF21 Improves the Adipocyte Dysfunction Related to Seipin Deficiency","volume":"65","author":"Dollet L","year":"2016","unstructured":"Dollet L, Levrel C, Coskun T, Le Lay S, Le May C, Ayer A, et al. FGF21 Improves the Adipocyte Dysfunction Related to Seipin Deficiency. Diabetes. 2016;65(11):3410\u20137.","journal-title":"Diabetes"},{"issue":"7","key":"ref23","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/gt.2014.38","article-title":"Targeting adipose tissue via systemic gene therapy","volume":"21","author":"O'Neill SM","year":"2014","unstructured":"O'Neill SM, Hinkle C, Chen SJ, Sandhu A, Hovhannisyan R, Stephan S, et al. Targeting adipose tissue via systemic gene therapy. Gene Ther. 2014;21(7):653\u201361.","journal-title":"Gene Ther"},{"issue":"8","key":"ref24","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708791","article-title":"FGF21 gene therapy as treatment for obesity and insulin resistance","volume":"10","author":"Jimenez V","year":"2018","unstructured":"Jimenez V, Jambrina C, Casana E, Sacristan V, Munoz S, Darriba S et al. FGF21 gene therapy as treatment for obesity and insulin resistance. EMBO Mol Med. 2018;10(8).","journal-title":"EMBO Mol Med"},{"issue":"9\u201310","key":"ref25","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41434-024-00471-z","article-title":"Preclinical evaluation of tissue-selective gene therapies for congenital generalised lipodystrophy","volume":"31","author":"Tiwari M","year":"2024","unstructured":"Tiwari M, Roumane A, Sommer N, Han W, Delibegovic M, Rochford JJ, et al. Preclinical evaluation of tissue-selective gene therapies for congenital generalised lipodystrophy. Gene Ther. 2024;31(9\u201310):445\u201354.","journal-title":"Gene Ther"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101500","article-title":"Dose-finding and in vivo safety study of an adipose targeted leptin gene therapy for congenital leptin deficiency","volume":"33","author":"Huang W","year":"2025","unstructured":"Huang W, Mohammed T, Zou X, Krishnan AA, Mo X, Xiao M, Cao L. Dose-finding and in vivo safety study of an adipose targeted leptin gene therapy for congenital leptin deficiency. Mol Ther Methods Clin Dev. 2025;33(3).","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/(SICI)1521-2254(199901\/02)1:1<31::AID-JGM3>3.0.CO;2-T","article-title":"Selective uptake and sustained expression of AAV vectors following subcutaneous delivery","volume":"1","author":"Donahue BA","year":"1999","unstructured":"Donahue BA, McArthur JG, Spratt SK, Bohl D, Lagarde C, Sanchez L, et al. Selective uptake and sustained expression of AAV vectors following subcutaneous delivery. J Gene Med. 1999;1(1):31\u201342.","journal-title":"J Gene Med"},{"issue":"8","key":"ref28","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1161\/CIRCRESAHA.118.313369","article-title":"In Vivo Ryr2 Editing Corrects Catecholaminergic Polymorphic Ventricular Tachycardia","volume":"123","author":"Pan X","year":"2018","unstructured":"Pan X, Philippen L, Lahiri SK, Lee C, Park SH, Word TA, et al. In Vivo Ryr2 Editing Corrects Catecholaminergic Polymorphic Ventricular Tachycardia. Circ Res. 2018;123(8):953\u201363.","journal-title":"Circ Res"},{"issue":"1\u20132","key":"ref29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1089\/hum.2020.113","article-title":"Gene Transfer in Adeno-Associated Virus Seropositive Rhesus Macaques Following Rapamycin Treatment and Subcutaneous Delivery of AAV6, but Not Retargeted AAV6 Vectors","volume":"32","author":"Stone D","year":"2021","unstructured":"Stone D, Kenkel EJ, Loprieno MA, Tanaka M, De Silva Feelixge HS, Kumar AJ, et al. Gene Transfer in Adeno-Associated Virus Seropositive Rhesus Macaques Following Rapamycin Treatment and Subcutaneous Delivery of AAV6, but Not Retargeted AAV6 Vectors. Hum Gene Ther. 2021;32(1\u20132):96\u2013112.","journal-title":"Hum Gene Ther"},{"issue":"6636","key":"ref30","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/43185","article-title":"Congenital leptin deficiency is associated with severe early-onset obesity in humans","volume":"387","author":"Montague CT","year":"1997","unstructured":"Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 1997;387(6636):903\u20138.","journal-title":"Nature"},{"issue":"9","key":"ref31","doi-asserted-by":"crossref","first-page":"101187","DOI":"10.1016\/j.xcrm.2023.101187","article-title":"High morbidity and mortality in children with untreated congenital deficiency of leptin or its receptor","volume":"4","author":"Saeed S","year":"2023","unstructured":"Saeed S, Khanam R, Janjua QM, Manzoor J, Ning L, Hanook S, et al. High morbidity and mortality in children with untreated congenital deficiency of leptin or its receptor. Cell Rep Med. 2023;4(9):101187.","journal-title":"Cell Rep Med"},{"issue":"8","key":"ref32","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1172\/JCI0215693","article-title":"Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine\/metabolic dysfunction of human congenital leptin deficiency","volume":"110","author":"Farooqi IS","year":"2002","unstructured":"Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine\/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002;110(8):1093\u2013103.","journal-title":"J Clin Invest"},{"issue":"10","key":"ref33","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1210\/jc.2004-0376","article-title":"Congenital leptin deficiency due to homozygosity for the Delta133G mutation: report of another case and evaluation of response to four years of leptin therapy","volume":"89","author":"Gibson WT","year":"2004","unstructured":"Gibson WT, Farooqi IS, Moreau M, DePaoli AM, Lawrence E, O'Rahilly S, et al. Congenital leptin deficiency due to homozygosity for the Delta133G mutation: report of another case and evaluation of response to four years of leptin therapy. J Clin Endocrinol Metab. 2004;89(10):4821\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"ref34","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral EA","year":"2002","unstructured":"Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346(8):570\u20138.","journal-title":"N Engl J Med"},{"issue":"11","key":"ref35","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s40264-014-0226-z","article-title":"Side effects of cytokines approved for therapy","volume":"37","author":"Baldo BA","year":"2014","unstructured":"Baldo BA. Side effects of cytokines approved for therapy. Drug Saf. 2014;37(11):921\u201343.","journal-title":"Drug Saf"},{"issue":"8","key":"ref36","doi-asserted-by":"crossref","first-page":"e12147","DOI":"10.1371\/journal.pone.0012147","article-title":"Hepatic gene expression profiling reveals key pathways involved in leptin-mediated weight loss in ob\/ob mice","volume":"5","author":"Sharma A","year":"2010","unstructured":"Sharma A, Bartell SM, Baile CA, Chen B, Podolsky RH, McIndoe RA, et al. Hepatic gene expression profiling reveals key pathways involved in leptin-mediated weight loss in ob\/ob mice. PLoS ONE. 2010;5(8):e12147.","journal-title":"PLoS ONE"},{"issue":"3","key":"ref37","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/ijo.2014.166","article-title":"Leptin administration activates irisin-induced myogenesis via nitric oxide-dependent mechanisms, but reduces its effect on subcutaneous fat browning in mice","volume":"39","author":"Rodriguez A","year":"2015","unstructured":"Rodriguez A, Becerril S, Mendez-Gimenez L, Ramirez B, Sainz N, Catalan V, et al. Leptin administration activates irisin-induced myogenesis via nitric oxide-dependent mechanisms, but reduces its effect on subcutaneous fat browning in mice. Int J Obes (Lond). 2015;39(3):397\u2013407.","journal-title":"Int J Obes (Lond)"},{"issue":"20","key":"ref38","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1101\/gad.12.20.3182","article-title":"Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy","volume":"12","author":"Shimomura I","year":"1998","unstructured":"Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, Goldstein JL, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev. 1998;12(20):3182\u201394.","journal-title":"Genes Dev"},{"issue":"3\u20134","key":"ref39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41434-023-00422-0","article-title":"Long-term effects of a fat-directed FGF21 gene therapy in aged female mice","volume":"31","author":"Anderson JM","year":"2024","unstructured":"Anderson JM, Arnold WD, Huang W, Ray A, Owendoff G, Cao L. Long-term effects of a fat-directed FGF21 gene therapy in aged female mice. Gene Ther. 2024;31(3\u20134):95\u2013104.","journal-title":"Gene Ther"},{"issue":"5","key":"ref40","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.ymthe.2019.02.011","article-title":"Adipocytes: A Novel Target for IL-15\/IL-15Ralpha Cancer Gene Therapy","volume":"27","author":"Xiao R","year":"2019","unstructured":"Xiao R, Mansour AG, Huang W, Chrislip LA, Wilkins RK, Queen NJ, et al. Adipocytes: A Novel Target for IL-15\/IL-15Ralpha Cancer Gene Therapy. Mol Ther. 2019;27(5):922\u201332.","journal-title":"Mol Ther"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7030870\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7030870\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T10:33:26Z","timestamp":1753180406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7030870\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":40,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-7030870\/v1","relation":{},"subject":[],"published":{"date-parts":[[2025,7,17]]},"subtype":"preprint"}}